Antibody–Drug Conjugates and Heart Risk in HER2-Positive Advanced Breast Cancer: What Clinicians Need to Know
Posted inCardiology news Oncology

Antibody–Drug Conjugates and Heart Risk in HER2-Positive Advanced Breast Cancer: What Clinicians Need to Know

A 2025 meta-analysis of 9,538 patients found trastuzumab emtansine (T‑DM1) carries the lowest incidence of LVEF decline (0.94%), while trastuzumab deruxtecan (T‑DXd) and trastuzumab-based combinations show similar, modest rates (≈4–5%). Trial selection and monitoring practices limit generalizability; baseline cardiac assessment and individualized surveillance remain essential.
Patritumab Deruxtecan Shows Promising Efficacy in HR+HER2− Advanced Breast Cancer After CDK4/6 Inhibitor Failure: Insights from ICARUS-BREAST01 Phase 2 Trial
Posted inClinical Updates news OB/GYN & Women's Health Oncology Specialties

Patritumab Deruxtecan Shows Promising Efficacy in HR+HER2− Advanced Breast Cancer After CDK4/6 Inhibitor Failure: Insights from ICARUS-BREAST01 Phase 2 Trial

The ICARUS-BREAST01 phase 2 trial demonstrated patritumab deruxtecan's efficacy and manageable safety in HR+HER2− metastatic breast cancer post-CDK4/6 inhibitors, highlighting key biomarkers linked to response and resistance.